Publication number |
CLPUB00783 |
Authors |
Stacey G.N., Hawkins J.R., Carter P., Hunt C.J., Young L.A. |
Title |
Replacement seed stock for MRC-5 cells. |
Citation |
(In technical document) World Health Organization publication WHO/BS/07.2077; pp.1-9; WHO; Geneva; Switzerland (2007) |
Web pages |
https://www.who.int/publications/m/item/replacement-seed-stock-for-mrc-5-cells-who-bs-07.2077 |
Abstract |
The original seed stock of MRC-5 cells ("PDL7") was established in the
1960s at the laboratories later known as the National Institute for
Biological Standards and Control in the UK. These original stocks have
been released by NIBSC for the development of vaccines over several
decades. MRC-5 cells are a human diploid fibroblast culture which can be
passaged in vitro for approximately 50 population doublings, when they
become senescent and cease to replicate i.e. they are a 'finite cell line'.
Manufacturers' stocks of these cells clearly need periodic replacement
from NIBSC and this has meant that NIBSC stocks of these cells have become
depleted. This fact, combined with an observed deterioration of the
original glass vials in which the cells were originally frozen resulted in
the need to replace the stocks supplied to manufacturers to ensure
continuity of supply of these cells for vaccine development.
NIBSC, with the support of the WHO ECBS and in liaison with manufacturers,
has produced a replacement bank of MRC-5 cells at a slightly higher
passage level than the original stock. This new bank of cells has
undergone a range of quality control tests and the results from these
tests have been deemed satisfactory.
This replacement stock of MRC-5 cells is now offered for adoption by ECBS
as a `reference cell bank' (as defined by the 'WHO Cell bank Monitoring
Group (WHO, 2003)), as a direct replacement for the original MRC-5 "PDL 7"
stock. The cell line data sheet and 'Information For Use' (IFU) that will
be released with the material are attached as appendices.
|
Cell lines |
CVCL_0440; MRC-5 CVCL_JF54; MRC-5 PDL12 |